Ichthyosis Clinical Trial
Official title:
Prospective Evaluation of Infants and Children With Congenital Ichthyosis
NCT number | NCT02655861 |
Other study ID # | 1504015620 |
Secondary ID | |
Status | Terminated |
Phase | |
First received | |
Last updated | |
Start date | June 2015 |
Est. completion date | June 5, 2019 |
Verified date | July 2020 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This project will follow babies with ichthyosis over time in order to better understand the natural course of ichthyosis in infants and children and to examine how specific genetic mutations affect clinical characteristics.
Status | Terminated |
Enrollment | 21 |
Est. completion date | June 5, 2019 |
Est. primary completion date | June 5, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 3 Years |
Eligibility |
Inclusion Criteria: - One parent must be able to understand and sign an informed consent document. - Newborns who present at or within 2 months of birth with a clinical diagnosis of ichthyosis. - Families must consent to providing DNA for genetic analysis - Families must agree to the intake evaluation followed by 10 follow-up evaluations, which will occur at ages 1, 2, 3, 6, 9, 12, 18, 24, and 36 months. Exclusion Criteria: - Subjects with non-English speaking parents - Patients with a family history of ichthyosis vulgaris - Patients with X-linked ichthyosis |
Country | Name | City | State |
---|---|---|---|
United States | Yale School of Medicine | New Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University | Foundation for Ichthyosis & Related Skin Types (FIRST) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Ear and Eye Conditions | To determine the incidence and severity of ear and eye problems in early childhood in relation to genotype, caregivers will be queried regarding buildup of ear debris and palpebral closure during sleep. Physical exams will assess ear canal patency, lid closure, and signs of conjunctival irritation. If participants are evaluated and/or treated by ophthalmology and otolaryngology, these records will be obtained. This outcome will be captured as a 'yes/no' for any or all of the above. | Birth (baseline), 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months, 36 months | |
Primary | Weight | To assess growth, birth weight and all weights (in pounds) obtained during hospitalization and clinic visits will be recorded. The primary outcome of the study will be to determine incidence, timing and severity of "growth failure" in neonates with ichthyosis in relation to genotype at the 3 year pediatric visit. Weight of the child will primarily be used to make this determination. | 36 Months | |
Primary | Length (Height) | To assess growth, birth length and all subsequent measures (in inches) obtained during hospitalization and clinic visits will be recorded. The primary outcome of the study will be to determine incidence, timing and severity of "growth failure" in neonates with ichthyosis in relation to genotype at the 3 year pediatric visit. Length of the child will primarily be used to make this determination. | 36 Months | |
Secondary | Weight | To assess growth, birth weight and all weights (in pounds) obtained during hospitalization and clinic visits will be recorded. Weight of the child will be used to characterize growth over the course of the 3 year follow up time. | Birth (baseline), 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months | |
Secondary | Length (Height) | To assess growth, birth length and all subsequent measures (in inches) obtained during hospitalization and clinic visits will be recorded. Length of the child will be used to characterize growth over the course of the 3 year follow up time. | Birth (baseline), 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months | |
Secondary | Electrolyte Disturbance | Measurements of electrolytes, including calcium, phosphate, magnesium, BUN and creatinine values will be used to evaluate the incidence, timing, and severity of electrolyte disturbances and the management of these disturbances in the neonatal period in relation to phenotypic group and to genotype. This outcome will be captured as a 'yes/no' for any or all of the above. | Birth (baseline), 1 month, 2 months, 3 months, 12 months, 24 months, 36 months | |
Secondary | Systemic Infections | The incidence, severity timing, and causative organisms of systemic infections during neonatal hospital stays will be reviewed in relation to management, including skin care practices and nursing procedures (e.g., open bed vs. humidified isolette). | Birth (baseline), 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months, 36 months | |
Secondary | Complications of Congenital Ichthyosis | Clinical severity will be rated using a standardized instrument. The evolution of skin phenotype will be documented via serial standardized photography. Transepidermal Water Loss (TEWL) will be measured in some sites. | Birth (baseline), 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months, 36 months | |
Secondary | Developmental Delays | To determine the incidence and severity of development delays in relation to genotype, a development history will be obtained at each follow-up evaluation, including information regarding relevant interventions such as physical or occupational therapy. Physical examination at each visit will assess range of motion of digital and major limb joints. This outcome will be captured as a 'yes/no' for any or all of the above. | Birth (baseline), 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months, 36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03051347 -
Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments
|
N/A | |
Completed |
NCT00004690 -
Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis
|
Phase 3 | |
Completed |
NCT00074685 -
National Registry for Ichthyosis and Related Disorders
|
||
Completed |
NCT03641261 -
Therapeutic Education Using an Internet Application in Hereditary Ichthyosis
|
N/A | |
Completed |
NCT03796052 -
Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients
|
N/A | |
Recruiting |
NCT05954416 -
FARD (RaDiCo Cohort) (RaDiCo-FARD)
|
||
Active, not recruiting |
NCT05295732 -
The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis
|
Phase 3 | |
Recruiting |
NCT03464994 -
Ophthalmological Abnormalities in Hereditary Ichthyosis (ICHTYO-KERATO)
|
N/A | |
Recruiting |
NCT03417856 -
Defining the Skin and Blood Biomarkers of Ichthyosis
|
||
Terminated |
NCT04697056 -
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
|
Phase 2 | |
Recruiting |
NCT06330350 -
Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling
|
||
Enrolling by invitation |
NCT06330324 -
Reproductive Options in Inherited Skin Diseases
|
||
Completed |
NCT03041038 -
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
|
Phase 2 | |
Not yet recruiting |
NCT06362447 -
Efficacy of Injectable Gentamicin in Hereditary Ichthyosis
|
Phase 2 | |
Active, not recruiting |
NCT04549792 -
An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses
|
Early Phase 1 |